William Blair Has Positive Outlook of argenx FY2026 Earnings
Equities researchers at William Blair increased their FY2026 EPS estimates for argenx in a research note issued on Friday, ...
William Blair Predicts First Solar Q1 Earnings
Analysts at William Blair issued their Q1 2025 earnings per share estimates for First Solar in a note issued to investors on ...
William Blair Reaffirms “Outperform” Rating for Vital Farms (NASDAQ:VITL)
William Blair reiterated their outperform rating on shares of Vital Farms (NASDAQ:VITL – Free Report) in a report published on Friday morning,RTT News reports. William Blair also issued estimates for ...
Q3 Earnings Forecast for Salesforce Issued By William Blair
Investment analysts at William Blair boosted their Q3 2026 earnings per share (EPS) estimates for shares of Salesforce in a ...
What is William Blair’s Forecast for VERV Q1 Earnings?
William Blair issued their Q1 2026 earnings estimates for shares of Verve Therapeutics in a report issued on Thursday, ...
Fintel on MSN2d
William Blair Initiates Coverage of BioAge Labs (BIOA) with Market Perform Recommendation
Fintel reports that on February 28, 2025, William Blair initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Market ...
Hosted on MSN2d
William Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform Recommendation
Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) ...
Fintel on MSN2d
William Blair Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Outperform Recommendation
Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary ...
Fintel on MSN2d
William Blair Initiates Coverage of Skye Bioscience (SKYE) with Outperform Recommendation
Fintel reports that on February 28, 2025, William Blair initiated coverage of Skye Bioscience (NasdaqGM:SKYE) with a ...
Xenon Pharmaceuticals’ (XENE) “Outperform” Rating Reiterated at William Blair
William Blair restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report ...